With a median follow-up of nearly 8 years, the CHAARTED (E3805) randomized phase III trial continues to demonstrate that androgen deprivation therapy (ADT) plus docetaxel chemotherapy significantly improves overall survival in men with metastatic hormone-sensitive prostate cancer, compared to ADT alone. Primary results were reported previously (Sweeney CJ. N Eng J Med. 2015).
Abhishek Tripathi, MD (University of Oklahoma Health Sciences Center), discusses the long-term survival data, which he presented at the 2022 Annual Meeting of the American Society of Clinical Oncology.